Syros Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Syros Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2015 to Q2 2024.
  • Syros Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$23.3M, a 35.7% increase year-over-year.
  • Syros Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$132M, a 38.4% decline year-over-year.
  • Syros Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$165M, a 73.9% decline from 2022.
  • Syros Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$94.7M, a 9.35% decline from 2021.
  • Syros Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$86.6M, a 3% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$132M -$23.3M +$12.9M +35.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 -$144M -$3.71M +$20.1M +84.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$165M -$64.4M -$59.6M -1249% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 -$105M -$40.1M -$9.89M -32.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$95.1M -$36.3M -$1.78M -5.15% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 -$93.3M -$23.8M +$1.36M +5.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$94.7M -$4.77M +$19M +80% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 -$114M -$30.3M -$4.23M -16.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$109M -$34.5M -$12M -53.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$97.5M -$25.1M -$10.9M -76.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 -$86.6M -$23.8M +$6.32M +21% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-02
Q3 2021 -$92.9M -$26M -$6.54M -33.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$86.3M -$22.5M -$5.29M -30.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$81M -$14.2M +$3M +17.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$84M -$30.1M -$10.4M -53% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 -$73.6M -$19.5M +$307K +1.55% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$73.9M -$17.2M +$2.26M +11.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$76.2M -$17.2M -$765K -4.65% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$75.4M -$19.7M -$1.64M -9.07% Oct 1, 2019 Dec 31, 2019 10-Q 2022-11-14
Q3 2019 -$73.8M -$19.8M -$4.06M -25.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$69.7M -$19.5M -$5.41M -38.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$64.3M -$16.5M -$2M -13.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$62.3M -$18.1M -$2.76M -18.1% Oct 1, 2018 Dec 31, 2018 10-Q 2021-11-05
Q3 2018 -$59.5M -$15.7M -$1.91M -13.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$57.6M -$14M -$679K -5.08% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 -$56.9M -$14.5M -$2.95M -25.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 -$54M -$15.3M -$4.33M -39.5% Oct 1, 2017 Dec 31, 2017 10-Q 2020-11-05
Q3 2017 -$49.7M -$13.8M +$344K +2.43% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$50M -$13.4M -$1.35M -11.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$48.7M -$11.5M -$927K -8.76% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$47.7M -$11M -$276K -2.58% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-12
Q3 2016 -$47.5M -$14.2M -$5.71M -67.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-12
Q2 2016 -$41.8M -$12M -$5.92M -97.2% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-12
Q1 2016 -$35.8M -$10.6M -$6.02M -132% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-12
Q4 2015 -$29.8M -$10.7M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-20
Q3 2015 -$8.46M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-20
Q2 2015 -$6.1M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-20
Q1 2015 -$4.57M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.